U.S. Markets closed
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • Dow 30

    35,911.81
    -201.79 (-0.56%)
     
  • Nasdaq

    14,893.75
    +86.95 (+0.59%)
     
  • Russell 2000

    2,162.46
    +3.02 (+0.14%)
     
  • Crude Oil

    84.62
    +0.80 (+0.95%)
     
  • Gold

    1,817.20
    +0.70 (+0.04%)
     
  • Silver

    22.96
    +0.04 (+0.18%)
     
  • EUR/USD

    1.1414
    -0.0046 (-0.3995%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • Vix

    19.19
    -1.12 (-5.51%)
     
  • GBP/USD

    1.3673
    -0.0037 (-0.2707%)
     
  • USD/JPY

    114.2640
    +0.0840 (+0.0736%)
     
  • BTC-USD

    43,210.92
    -79.41 (-0.18%)
     
  • CMC Crypto 200

    1,037.76
    +12.03 (+1.17%)
     
  • FTSE 100

    7,542.95
    -20.90 (-0.28%)
     
  • Nikkei 225

    28,124.28
    -364.82 (-1.28%)
     

Novo Nordisk's Higher Dose Of Semaglutide Trumped 1-mg Predecessor On Blood Sugar, Weight Reduction

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Novo Nordisk A/S (NYSE: NVO) announced data from SUSTAIN FORTE Phase 3b trial comparing semaglutide 2.0 mg versus 1.0 mg dose as an add-on to metformin in type 2 diabetes in need of additional blood sugar reduction.

  • The results were presented at the Annual Scientific Sessions of the American Diabetes Association, and the preliminary results will be published in The Lancet Diabetes & Endocrinology.

  • In the 961-patient study, higher-dose Ozempic patients saw an A1C reduction of 2.2% after 40 weeks of treatment versus a 1.9% reduction in the 1 mg Ozempic arm.

  • Meanwhile, subgroup analyses after the study wrapped showed that Ozempic 2 mg topped the lower dose in patients across a range of baseline blood sugar levels.

  • Patients who came into the study with a mean A1C of less than 9% saw a 1.9% reduction in the higher dose compared to a 1.7% reduction in the 1-mg arm reduction.

  • Patients with baseline A1C of at least 9% saw reductions of 2.6% versus 2.3% among patients on the lower dose.

  • Ozempic 2 mg helped patients lose 6.9 kg, statistically significant compared with the 6 kg lost by patients on the lower dose, provided they took the drug as directed.

  • Ozempic already comes in 0.5 mg and 1 mg doses injected weekly.

  • The data bodes well for Ozempic 2 mg’s application at the FDA, which Novo re-submitted in May.

  • Price Action: NVO shares closed at $82.8 on Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.